Health Economics›Mantle cell lymphoma›First-line therapy randomized data

First-line therapy randomized data

Mantle cell lymphoma · 11 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
IR-CHOP/R-DHAOx Variant #01	—	R 130 385	21d	—	—	~6	~R 546 584 indirect	—
IR-CHOP/R-DHAP Variant #01	—	R 129 392	21d	—	—	~6	~R 543 605 indirect	—
R-Hyper-CVAD/R-MA Variant #01	—	R 115 130	—	—	—	~4	~R 253 282 indirect	—
R-CHOP/R-DHAOx Variant #01	—	R 57 884	21d	—	—	~6	~R 329 080 indirect	—
Bendamustine and Rituximab (BR) Variant #01	—	R 33 874	28d	51.3 mo	—	8	R 270 994 PFS proxy	4
VR-CAP Variant #01	—	R 33 397	21d	24.7 mo	90.7 mo	8	R 267 178 PFS proxy	2
R-CHOP/R-DHAP Variant #01	—	R 30 986	21d	—	—	~6	~R 170 673 indirect	—
R-CHOP (Prednisolone) Variant #01	—	R 26 953	21d	42.4 mo	—	6	R 161 716 PFS proxy	—
R-CHOP Variant #08	—	R 26 946	21d	14.4 mo	55.7 mo	9	R 242 515 PFS proxy	3
R-CHOP-14 (Prednisolone) Variant #01	—	R 26 789	14d	—	—	~8	~R 212 546 PFS proxy · indirect	1
R-CVP Variant #01	—	R 26 502	21d	—	—	~3	~R 79 505 PFS proxy · indirect	1

11 of 11 regimens shown